If you’re able to buy BlackRock, Inc. BLK, according to Jim Cramer, then it’s “an amazing quarter.” The Securities and Exchange Commission (SEC) extended the judgement deadline for the proposed Ethereum exchange-traded fund by BlackRock to March 10.
When it comes to Axsome Therapeutics, Inc. AXSM, Cramer admitted he needed to do more research, as the central nervous system has been a thorn in the side of many companies. RBC Capital initiated coverage on Axsome Therapeutics, citing that its near-term revenue growth and pipeline optionality are underappreciated.
Axsome’s recent fourth quarter 2023 product revenue of approximately $71 million and $204 million for the full year of 2023 indicates a respectable performance.
But as for SolarEdge Technologies, Inc. SEDG, Cramer expressed reluctance, noting that it and Enphase Energy, Inc., are “just too hard to own.”
SolarEdge Technologies recently announced a significant 16% reduction of its workforce, affecting approximately 900 employees, with the goal of aligning its cost structure to current market dynamics. Goldman Sachs analyst Brian Lee maintained SolarEdge Technologies with a Sell rating and lowered the price target from $83 to $71.
Shares of SolarEdge gained 0.3% to close at $70.44, while Enphase shares fell 1.2% to $106.83 on Thursday. BlackRock shares gained 0.6% to settle at $790.46, while Axsome Therapeutics fell 1.3% to $90.59 during Thursday’s session.
